Anticipate Dispensing Post-Exposure Prophylaxis for COVID-19
You'll hear buzz about casirivimab/imdevimab (Regen-COV), the first med authorized to PREVENT COVID-19 after exposure.
This monoclonal antibody is already authorized to TREAT certain outpatients 12 or older with COVID-19 who are at high risk for severe illness...such as those with diabetes, obesity, etc.
Now it may be used for COVID-19 prevention if these same high-risk patients are exposed to the virus...as "post-exposure prophylaxis."
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote